Spero Therapeutics Inc (SPRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Spero Therapeutics Inc (SPRO) has a cash flow conversion efficiency ratio of -0.141x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.35 Million) by net assets ($59.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Spero Therapeutics Inc for the company's overall valuation and market capitalisation.
Spero Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Spero Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Spero Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spero Therapeutics Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Spero Therapeutics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aquila European Renewables Income PLC
LSE:AERI
|
0.005x |
|
Evertex Fabrinology Ltd
TW:1470
|
0.041x |
|
Decidr Ai Industries Ltd
AU:DAI
|
-0.079x |
|
Value8 N.V
AS:VALUE
|
0.007x |
|
Done.ai Group AB
ST:DONE
|
-0.014x |
|
Schnapp
TA:SHNP
|
0.024x |
|
Innoviz Technologies
NASDAQ:INVZ
|
-0.153x |
|
Solutions 30 SE
F:30L3
|
-0.234x |
Annual Cash Flow Conversion Efficiency for Spero Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Spero Therapeutics Inc from 2015 to 2025. View SPRO live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $59.02 Million | $-12.62 Million | -0.214x | +57.92% |
| 2024-12-31 | $46.12 Million | $-23.44 Million | -0.508x | -64.67% |
| 2023-12-31 | $106.89 Million | $-32.99 Million | -0.309x | -203.18% |
| 2022-12-31 | $75.93 Million | $-7.73 Million | -0.102x | +86.03% |
| 2021-12-31 | $88.29 Million | $-64.35 Million | -0.729x | -12.07% |
| 2020-12-31 | $132.04 Million | $-85.87 Million | -0.650x | +3.04% |
| 2019-12-31 | $74.57 Million | $-50.02 Million | -0.671x | -96.11% |
| 2018-12-31 | $115.86 Million | $-39.62 Million | -0.342x | +25.71% |
| 2017-12-31 | $84.96 Million | $-39.11 Million | -0.460x | +89.89% |
| 2016-12-31 | $6.36 Million | $-28.96 Million | -4.553x | -112.18% |
| 2015-12-31 | $-257.00K | $-9.61 Million | 37.385x | -- |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more